The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy: The TAC-HFT Randomized Trial
Open accessAbstract
IMPORTANCE: Whether culture-expanded mesenchymal stem cells or whole bone marrow mononuclear cells are safe and effective in chronic ischemic cardiomyopathy is controversial. OBJECTIVE: To demonstrate the safety of transendocardial stem cell injection with autologous mesenchymal stem cells (MSCs) and bone marrow mononuclear cells (BMCs) in patients with ischemic cardiomyopathy. DESIGN, SETTING, AND PATIENTS: A phase 1 and 2 randomized, blinded, placebo-controlled study involving 65 patients with ischemic cardiomyopathy and left ventricular (LV) ejection fraction less than 50% (September 1, 2009-July 12, 2013). The study compared injection of MSCs (n=19) with placebo (n = 11) and BMCs (n = 19) with placebo (n = 10), with 1 year of follow-up. INTERVENTIONS: Injections in 10 LV sites with an infusion catheter. MAIN OUTCOMES AND MEASURES: Treatment-emergent 30-day serious adverse event rate defined as a composite of death, myocardial infarction, stroke, hospitalization for worsening heart failure, perforation, tamponade, or sustained ventricular arrhythmias. RESULTS: No patient had a treatment-emergent serious adverse events at day 30. The 1-year incidence of serious adverse events was 31.6% (95% CI, 12.6% to 56.6%) for MSCs, 31.6% (95% CI, 12.6%-56.6%) for BMCs, and 38.1% (95% CI, 18.1%-61.6%) for placebo. Over 1 year, the Minnesota Living With Heart Failure score improved with MSCs (-6.3; 95% CI, -15.0 to 2.4; repeated measures of variance, P=.02) and with BMCs (-8.2; 95% CI, -17.4 to 0.97; P=.005) but not with placebo (0.4; 95% CI, -9.45 to 10.25; P=.38). The 6-minute walk distance increased with MSCs only (repeated measures model, P = .03). Infarct size as a percentage of LV mass was reduced by MSCs (-18.9%; 95% CI, -30.4 to -7.4; within-group, P = .004) but not by BMCs (-7.0%; 95% CI, -15.7% to 1.7%; within-group, P = .11) or placebo (-5.2%; 95% CI, -16.8% to 6.5%; within-group, P = .36). Regional myocardial function as peak Eulerian circumferential strain at the site of injection improved with MSCs (-4.9; 95% CI, -13.3 to 3.5; within-group repeated measures, P = .03) but not BMCs (-2.1; 95% CI, -5.5 to 1.3; P = .21) or placebo (-0.03; 95% CI, -1.9 to 1.9; P = .14). Left ventricular chamber volume and ejection fraction did not change. CONCLUSIONS AND RELEVANCE: Transendocardial stem cell injection with MSCs or BMCs appeared to be safe for patients with chronic ischemic cardiomyopathy and LV dysfunction. Although the sample size and multiple comparisons preclude a definitive statement about safety and clinical effect, these results provide the basis for larger studies to provide definitive evidence about safety and to assess efficacy of this new therapeutic approach. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00768066.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bolli, R., Chugh, A. R., D'Amario, D., Loughran, J. H., Stoddard, M. F., Ikram, S., Beache, G. M., Wagner, S. G., Leri, A., Hosoda, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61590-0 · Cited by 1,288
RetractedMultilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Wollert, K. C., Meyer, G. P., Lotz, J., Ringes Lichtenberg, S., Lippolt, P., Breidenbach, C., Fichtner, S., Korte, T., Hornig, B., Messinger, D., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16626-9 · Cited by 2,191
Hare, J. M., Traverse, J. H., Henry, T. D., Dib, N., Strumpf, R. K., Schulman, S. P., Gerstenblith, G., DeMaria, A. N., Denktas, A. E., Gammon, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.055 · Cited by 1,350
Self-citationJanssens, S., Dubois, C., Bogaert, J., Theunissen, K., Deroose, C., Desmet, W., Kalantzi, M., Herbots, L., Sinnaeve, P., Dens, J., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67861-0 · Cited by 1,294
Hare, J. M., Fishman, J. E., Gerstenblith, G., DiFede Velazquez, D. L., Zambrano, J. P., Suncion, V. Y., Tracy, M., Ghersin, E., Johnston, P. V., Brinker, J. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.25321 · Cited by 1,192
Self-citationTranscoronary Transplantation of Progenitor Cells after Myocardial Infarction
Assmus, B., Honold, J., Schächinger, V., Britten, M. B., Fischer-Rasokat, U., Lehmann, R., Teupe, C., Pistorius, K., Martin, H., Abolmaali, N. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051779 · Cited by 1,040
Williams, A. R., & Hare, J. M. (2011) · Circulation Research · doi:10.1161/circresaha.111.243147 · Cited by 886
Self-citationSilva, G. V., Litovsky, S., Assad, J. A. R., Sousa, A. L. S., Martin, B. J., Vela, D., Coulter, S. C., Lin, J., Ober, J., Vaughn, W. K., et al. (2005) · Circulation · doi:10.1161/01.cir.0000151812.86142.45 · Cited by 801
Bone Marrow Mesenchymal Stem Cells Stimulate Cardiac Stem Cell Proliferation and Differentiation
Hatzistergos, K. E., Quevedo, H., Oskouei, B. N., Hu, Q., Feigenbaum, G. S., Margitich, I. S., Mazhari, R., Boyle, A. J., Zambrano, J. P., Rodriguez, J. E., et al. (2010) · Circulation Research · doi:10.1161/circresaha.110.222703 · Cited by 715
Self-citation
Cited by
Stem Cell Therapies in Clinical Trials: Progress and Challenges
Trounson, A., & McDonald, C. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.06.007 · Cited by 1,468
Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases
Shi, Y., Wang, Y., Li, Q., Liu, K., Hou, J., Shao, C., & Wang, Y. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0023-5 · Cited by 1,223
Stem cell-based therapy for human diseases
Hoang, D. M., Pham, P. T., Bach, T. Q., Ngo, A. T. L., Nguyen, Q. T., Phan, T. T. K., Nguyen, G. H., Le, P. T. T., Hoang, V. T., Forsyth, N. R., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01134-4 · Cited by 1,074
The war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement
Ullah, M., Liu, D. D., & Thakor, A. S. (2019) · iScience · doi:10.1016/j.isci.2019.05.004 · Cited by 549
Bartolucci, J., Verdugo, F. J., González, P. L., Larrea, R. E., Abarzua, E., Goset, C., Rojo, P., Palma, I., Lamich, R., Pedreros, P. A., et al. (2017) · Circulation Research · doi:10.1161/circresaha.117.310712 · Cited by 487
Use of Mesenchymal Stem Cells for Therapy of Cardiac Disease
Karantalis, V., & Hare, J. M. (2015) · Circulation Research · doi:10.1161/circresaha.116.303614 · Cited by 425
Self-citationHeart Failure: Diagnosis, Management and Utilization
Inamdar, A., & Inamdar, A. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5070062 · Cited by 412
Mesenchymal Stem Cells Current Clinical Applications: A Systematic Review
Rodríguez-Fuentes, D. E., Fernández-Garza, L. E., Samia-Meza, J. A., Barrera-Barrera, S. A., Caplan, A. I., & Barrera-Saldaña, H. A. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.08.006 · Cited by 376
Hare, J. M., DiFede, D. L., Rieger, A. C., Florea, V., Landin, A. M., El-Khorazaty, J., Khan, A., Mushtaq, M., Lowery, M. H., Byrnes, J. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.009 · Cited by 355
Self-citationKarantalis, V., DiFede, D. L., Gerstenblith, G., Pham, S., Symes, J., Zambrano, J. P., Fishman, J., Pattany, P., McNiece, I., Conte, J., et al. (2014) · Circulation Research · doi:10.1161/circresaha.114.303180 · Cited by 348
Self-citationMathiasen, A. B., Qayyum, A. A., Jørgensen, E., Helqvist, S., Fischer-Nielsen, A., Kofoed, K. F., Haack-Sørensen, M., Ekblond, A., & Kastrup, J. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv136 · Cited by 344
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01855-9 · Cited by 343
Golpanian, S., Wolf, A., Hatzistergos, K. E., & Hare, J. M. (2016) · Physiological Reviews · doi:10.1152/physrev.00019.2015 · Cited by 343
Self-citationMesenchymal Stem Cell-Based Therapy for Cardiovascular Disease: Progress and Challenges
Bagno, L., Hatzistergos, K. E., Balkan, W., & Hare, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.009 · Cited by 337
Self-citationAdult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review
Nguyen, P. K., Rhee, J.-W., & Wu, J. C. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2225 · Cited by 299
Cell therapy for cardiac repair—lessons from clinical trials
Behfar, A., Crespo-Diaz, R., Terzic, A., & Gersh, B. J. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.9 · Cited by 292
Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis
Walter, J., Ware, L. B., & Matthay, M. A. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70217-6 · Cited by 278
Proangiogenic Features of Mesenchymal Stem Cells and Their Therapeutic Applications
Tao, H., Han, Z., Han, Z. C., & Li, Z. (2016) · Stem Cells International · doi:10.1155/2016/1314709 · Cited by 276
Cell therapy trials for heart regeneration — lessons learned and future directions
Menasché, P. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0013-0 · Cited by 272
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
Fisher, S. A., Doree, C., Mathur, A., Taggart, D. P., & Martin-Rendon, E. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007888.pub3 · Cited by 254
Glassberg, M. K., Minkiewicz, J., Toonkel, R. L., Simonet, E. S., Rubio, G. A., DiFede, D., Shafazand, S., Khan, A., Pujol, M. V., LaRussa, V. F., et al. (2017) · Chest · doi:10.1016/j.chest.2016.10.061 · Cited by 249
Self-citationBioengineering approaches to treat the failing heart: from cell biology to 3D printing
Yadid, M., Oved, H., Silberman, E., & Dvir, T. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00603-7 · Cited by 83
Sheikhi, K., Ghaderi, S., Firouzi, H., Rahimibarghani, S., Shabani, E., Afkhami, H., & Yarahmadi, A. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1517369 · Cited by 20
TWIST1 and TSG6 are coordinately regulated and function as potency biomarkers in human MSCs
Lee, R. H., Boregowda, S. V., Shigemoto-Kuroda, T., Bae, E., Haga, C. L., Abbery, C. A., Bayless, K. J., Haskell, A., Gregory, C. A., Ortiz, L. A., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi2387 · Cited by 16
Metadata
- Authors
- Heldman, A. W., DiFede, D. L., Fishman, J. E., Zambrano, J. P., Trachtenberg, B. H., Karantalis, V., Mushtaq, M., Williams, A. R., Suncion, V. Y., McNiece, I. K., Ghersin, E., Soto, V., Lopera, G., Miki, R., Willens, H., Hendel, R., Mitrani, R., Pattany, P., Feigenbaum, G., Oskouei, B., Byrnes, J., Lowery, M. H., Sierra, J., Pujol, M. V., Delgado, C., Gonzalez, P. J., Rodriguez, J. E., Bagno, L. L., Rouy, D., Altman, P., Foo, C. W. P., da Silva, J., Anderson, E., Schwarz, R., Mendizabal, A., & Hare, J. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-01-01
- Volume
- 311
- Issue
- 1
- Pages
- 62
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1981724886
- Cited by
- 570
- References
- 36
- FWCI
- 27.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.